Literature DB >> 18639915

Functional domain organization of human APOBEC3G.

Barry D Gooch1, Bryan R Cullen.   

Abstract

Human APOBEC3 proteins exist in two forms containing either a single cytidine deaminase domain (CDA) or two CDAs. Strikingly, the proteins that are capable of effectively inhibiting the infectivity of Vif-deficient HIV-1 (HIV-1DeltaVif), such as APOBEC3G (A3G), contain two CDAs. In contrast, single-domain APOBEC3 proteins such as APOBEC3A (A3A) are weak inhibitors of HIV-1DeltaVif, even though A3A is an active cytidine deaminase and a potent inhibitor of retrotransposon mobility. Here, we demonstrate that the ability to bind to Gag and package into HIV-1 virions is entirely contained within the amino-terminal half of A3G. By changing three adjacent amino acids in A3A, to the sequence found in the N-terminal half of A3G, we were able to confer on A3A the ability to be efficiently incorporated into HIV-1 virions and to bind HIV-1 Gag. Nevertheless, this A3A mutant remained a weak inhibitor of HIV-1 infectivity, suggesting that segregation of the Gag-binding/virion incorporation and cytidine deaminase/virus-inhibition activities of APOBEC3 proteins into two tandem CDA regions promotes the efficient inhibition of retrovirus infectivity by APOBEC3 proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18639915      PMCID: PMC2601658          DOI: 10.1016/j.virol.2008.06.013

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  45 in total

1.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

2.  Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.

Authors:  Andrew Mehle; Bettina Strack; Petronela Ancuta; Chengsheng Zhang; Mark McPike; Dana Gabuzda
Journal:  J Biol Chem       Date:  2003-12-13       Impact factor: 5.157

3.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

4.  The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.

Authors:  Silvestro G Conticello; Reuben S Harris; Michael S Neuberger
Journal:  Curr Biol       Date:  2003-11-11       Impact factor: 10.834

5.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G.

Authors:  Kuan-Ming Chen; Elena Harjes; Phillip J Gross; Amr Fahmy; Yongjian Lu; Keisuke Shindo; Reuben S Harris; Hiroshi Matsuo
Journal:  Nature       Date:  2008-02-20       Impact factor: 49.962

7.  Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression.

Authors:  Kim-Lien Nguyen; Manuel llano; Hirofumi Akari; Eri Miyagi; Eric M Poeschla; Klaus Strebel; Stephan Bour
Journal:  Virology       Date:  2004-02-20       Impact factor: 3.616

8.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

9.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.

Authors:  Mariana Marin; Kristine M Rose; Susan L Kozak; David Kabat
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

10.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Authors:  Ann M Sheehy; Nathan C Gaddis; Michael H Malim
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

View more
  20 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

Review 2.  The current structural and functional understanding of APOBEC deaminases.

Authors:  Ronda Bransteitter; Courtney Prochnow; Xiaojiang S Chen
Journal:  Cell Mol Life Sci       Date:  2009-06-23       Impact factor: 9.261

3.  Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities.

Authors:  Yannick Bulliard; Iñigo Narvaiza; Alessandro Bertero; Shyam Peddi; Ute F Röhrig; Millán Ortiz; Vincent Zoete; Nataly Castro-Díaz; Priscilla Turelli; Amalio Telenti; Olivier Michielin; Matthew D Weitzman; Didier Trono
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

4.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

Review 5.  Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.

Authors:  Jessica L Smith; Wei Bu; Ryan C Burdick; Vinay K Pathak
Journal:  Trends Pharmacol Sci       Date:  2009-12       Impact factor: 14.819

6.  HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain.

Authors:  Yasumasa Iwatani; Denise S B Chan; Lin Liu; Hiroaki Yoshii; Junko Shibata; Naoki Yamamoto; Judith G Levin; Angela M Gronenborn; Wataru Sugiura
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-03       Impact factor: 11.205

7.  Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization.

Authors:  Ying Dang; Xiaojun Wang; Tao Zhou; Ian A York; Yong-Hui Zheng
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

8.  Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain.

Authors:  Markus-Frederik Bohn; Shivender M D Shandilya; John S Albin; Takahide Kouno; Brett D Anderson; Rebecca M McDougle; Michael A Carpenter; Anurag Rathore; Leah Evans; Ahkillah N Davis; Jingying Zhang; Yongjian Lu; Mohan Somasundaran; Hiroshi Matsuo; Reuben S Harris; Celia A Schiffer
Journal:  Structure       Date:  2013-05-16       Impact factor: 5.006

9.  A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G.

Authors:  Gongying Chen; Zhiwen He; Tao Wang; Rongzhen Xu; Xiao-Fang Yu
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

10.  Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis.

Authors:  Delphine Lavens; Frank Peelman; José Van der Heyden; Isabel Uyttendaele; Dominiek Catteeuw; Annick Verhee; Bertrand Van Schoubroeck; Julia Kurth; Sabine Hallenberger; Reginald Clayton; Jan Tavernier
Journal:  Nucleic Acids Res       Date:  2009-12-16       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.